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Re-examining the high-density lipoprotein
hypothesis
A low level of high-density lipoprotein cholesterol (HDL-C) is
an important cardiovascular risk factor, and is commonly seen
in patients with type 2 diabetes mellitus. An inverse relation-
ship between HDL-C concentration and cardiovascular risk has
been consistently shown in clinical and epidemiological studies.
In the well-known Framingham Heart Study, HDL-C was
found to be the best predictor of cardiovascular mortality. The
recent Emerging Risk Factors Collaboration Study has also
shown that the strong inverse association between the risk of
coronary artery disease and HDL-C levels remained even after
adjusting for other lipid and non-lipid risk factors. As a key
independent cardiovascular risk factor, measurement of HDL-C
has been incorporated into the majority of the risk stratiﬁcation
models for prediction of cardiovascular risk. It has been esti-
mated that cardiovascular risk decreases by approximately 2–
3% per 1-mg/dL increase in HDL-C. In light of the strong
experimental and epidemiological data supporting a protective
role for HDL in atherosclerosis, substantial research efforts have
been directed at developing strategies to harness the ‘atheropro-
tective’ function of HDL, and raising HDL-C has become a
potential therapeutic target over the past decade.
However, the ‘HDL hypothesis’ suggesting that HDL plays a
causal role in the pathogenesis of atherosclerotic cardiovascular
disease has recently been challenged by large-scale human
genetic studies. The ﬁrst genetic study to cast doubt on the cau-
sal role of HDL used a Mendelian randomization approach to
determine whether single-nucleotide polymorphisms (SNPs)
associated with increased levels of HDL-C were also linked to
changes in the risk of coronary heart disease. Voight et al.1
reported that SNPs associated with high levels of low-density
lipoprotein cholesterol increased the risk of myocardial infarc-
tion, but surprisingly, no relationship could be found between
SNPs that raised HDL-C and coronary heart disease risk. Fur-
thermore, subsequent genome-wide association studies also
failed to show correlations between the magnitude of the effect
size of additional HDL-associated SNPs identiﬁed and the mag-
nitude of the effect size on coronary heart disease. These analy-
ses have therefore created skepticism about the causal role of
HDL in atherosclerotic cardiovascular disease.
Another severe blow to the HDL hypothesis comes from the
disappointing results of a number of clinical trials on agents
raising HDL-C. So far, pharmacological interventions that
increase HDL-C concentration have not shown improvement
in cardiovascular outcomes when added to standard statin ther-
apy2. Two large trials with the currently available major HDL-
C raising agent, niacin – the Atherothrombosis Intervention in
Metabolic syndrome with low HDL/high triglycerides: impact
on Global Health outcomes (AIM-HIGH) trial and the Heart
Protection Study 2 – Treatment of HDL to Reduce the Inci-
dence of Vascular Events (HPS2-THRIVE) – failed to show sig-
niﬁcant cardiovascular beneﬁt. This would suggest that raising
HDL-C levels, at least with niacin, did not confer any addi-
tional clinical beneﬁt on top of that achieved by statin therapy.
Inhibitors of cholesteryl ester transfer protein (CETP), which
are being developed speciﬁcally as HDL-C raising drugs,
increase HDL-C to a much greater extent than niacin. Short-
term clinical trials have demonstrated up to 60–70% increase in
HDL-C with some of the more potent CETP inhibitors. How-
ever, torcetrapib, the ﬁrst CETP inhibitor to enter clinical devel-
opment, not only failed to reduce cardiovascular risk but
actually increased cardiovascular and total mortality due to its
off-target effects. The Dal-OUTCOMES study, a phase 3 pla-
cebo-controlled randomized controlled trial of dalcetrapib in
patients with a recent acute coronary syndrome, was stopped
early after no signiﬁcant improvement in overall or cardiovas-
cular related mortality and related events was found. It has just
been announced that the development of another CETP inhibi-
tor, evacetrapib, would be discontinued after independent data
monitoring committee advised a halt to the phase 3 random-
ized trial in patients with high risk coronary artery disease
[Assessment of clinical effects of cholesteryl ester transfer pro-
tein inhibition with evacetrapib in patients at a high-risk for
vascular outcomes (ACCELERATE)] due to insufﬁcient efﬁcacy.
This leaves the Randomized Evaluation of the Effects of Anace-
trapib through Lipid-modiﬁcation (REVEAL) trial as the only
ongoing phase 3 cardiovascular outcome trial of CETP inhibitor
in patients with established vascular disease. The trial is
expected to be completed in 2017 and the results will be critical
in determining whether CETP inhibitor has a place in clinical
care.
So is the ‘HDL hypothesis’ truly defunct? It should be
pointed out that the HDL hypothesis has always been related
to HDL function rather than to HDL-C content. Simply raising
levels of HDL-C level cannot be directly inferred to as improv-
ing HDL function. Likewise, in human genetic studies, the
extent to which the SNPs that are associated with increases in
HDL-C are also linked to relevant changes in HDL function is
uncertain. It is clear that the complex nature of HDL metabo-
lism and function cannot be determined by just quantifying
HDL-C alone. HDL particles are highly heterogeneous and
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consist of multiple forms and components, and this heterogene-
ity in HDL structure is intrinsically related to their functional
diversity. Measurement of HDL-C content does not necessarily
reﬂect the distribution or overall abundance of HDL subspecies.
Structure-function analyses have shown that HDL-C is a rather
poor indicator of the functionality of HDL. Experimental data
have suggested that HDL has multiple protective functions
against atherosclerosis. One of the best characterized functions
of HDL is its role in reverse cholesterol transport. By acting as
extracellular cholesterol acceptors in the circulation, HDL can
promote cholesterol efﬂux from cells like macrophages in the
artery wall (Figure 1). In addition, HDL has anti-oxidative,
anti-inﬂammatory and anti-apoptotic properties. HDL has been
reported to block oxidative modiﬁcation of LDL and decrease
adhesion molecules expression. It also promotes endothelial
repair and ameliorates endothelial dysfunction. Which subclass
(es) of HDL species are responsible for which aspects of biolog-
ical activities of HDL is poorly understood. To make matters
even more complicated, changes in the proteome and/or lipi-
dome of HDL particle may adversely affect the functionality of
HDL. A number of pathological conditions including diabetes
mellitus can trigger structural and functional alterations in
HDL and many proteins other than apolipoproteins may bind
to HDL. One such example is serum amyloid A, and binding
of serum amyloid A impairs the ability of HDL to efﬂux
cholesterol from cells3. As a result, HDL can lose its atheropro-
tective properties, and become dysfunctional and pro-inﬂamma-
tory under certain circumstances. The degree of loss of normal
HDL function and gain of dysfunction might differ with respect
to the different biological activities of HDL. How changes in
the proteome and/or lipidome of HDL affect the functionality
of HDL is currently under intense investigations.
Clinical measures to determine the different aspects of HDL
function are being developed and evaluated in a number of
research laboratories. The most widely-studied and well-charac-
terized HDL function is probably its cholesterol efﬂux capacity.
Ex vivo assays have been used to assess the capacity of individ-
ual patient HDL specimens or serum to remove cholesterol
from cultured cholesterol-loaded macrophages. The relationship
between HDL cholesterol efﬂux capacity and cardiovascular dis-
ease has been examined in cross-sectional and longitudinal
studies. It has been shown that HDL-C levels only explain a
fraction (approximately one-third) of the variance in the choles-
terol efﬂux capacity of HDL. An independent inverse associa-
tion between HDL cholesterol efﬂux capacity and incident
cardiovascular events has been shown both in the Dallas Heart
Study and in the European Prospective Investigation of Cancer-
Norfolk study4,5. Measurement of this classic function of HDL
has an even stronger relationship with coronary heart disease
than measures of HDL-C, and the relevance of HDL function-
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Figure 1 | Cellular cholesterol efflux to high-density lipoprotein (HDL). Efflux of free cholesterol (FC) from cells to extracellular HDL-based acceptors
is mediated by the action of active transporters and passive diffusion. This first step of reverse cholesterol transport is influenced by the
physicochemical properties of HDL and the interaction of these HDL subclasses with cellular transporters. The adenosine triphosphate-binding
cassette transporter A1 (ABCA1) interacts with cholesterol-deficient and phospholipid-depleted apolipoprotein A-I complexes, whereas ABCG1 and
scavenger receptor B1 (SRB1) interact with spherical HDL particles of various sizes. After efflux to HDL, FC is esterified in the plasma by lecithin-
cholesterol acyltransferase (LCAT), and is ultimately transported from HDL to the liver, either directly through SRBI or after transfer to
apolipoprotein B-containing lipoproteins by the cholesteryl ester transfer protein for ultimate disposal in the feces.
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ality to cardiovascular disease has ﬁnally been conﬁrmed in
these clinical studies. Taken together, available data show that
HDL cholesterol efﬂux capacity is predictive of prevalent and
incident coronary heart disease independent of HDL-C, and
evaluation of HDL function rather than HDL mass such as
HDL-C might be much more informative.
In conclusion, HDL-C is not a good surrogate marker of
HDL function. Measurement(s) of HDL function rather than
HDL-C might be a better tool to evaluate the therapeutic
response of interventions targeting HDL, and could also fur-
ther improve the assessment of cardiovascular risk. However,
standardized assays of HDL function are not yet available for
routine clinical use, and a number of issues need to be
addressed. As HDL has multiple functions, there is currently
no consensus on which function(s) of HDL are key to its
antiatherogenic effect, and what the optimal test(s) to charac-
terize HDL function are. Because of the heterogeneity of HDL,
measurement of HDL particles and distribution of subspecies
needs to be validated in order to standardize assays of func-
tionality with HDL quantiﬁcation. The assays of HDL function
also need to be reproducible and cost-effective. HDL is one of
the most biologically variable molecules, and the ‘HDL func-
tion hypothesis’ still holds potential as a means to reduce car-
diovascular disease.
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